Treatment of Metastatic Pancreatic Neuroendocrine Tumors: Relevance of ENETS 2016 Guidelines

#1590

Introduction: The choice of first-line treatment of metastatic pancreatic neuroendocrine tumors (mP-NET) is mainly based on prognostic factors. ENETS-2016 guidelines proposed treatments according to 3 groups: Group-1, patients in whom all lesions could be removed; Group-2, patients with Ki67<10%, low tumor burden, no symptoms, and stable disease, for whom a watch-and-wait strategy or somatostatin analogs are proposed; Group-3, symptomatic patients or with Ki67>10% or significant tumor burden or progressive disease, for whom a systemic chemotherapy is proposed

Aim(s): This study aimed to determine distribution, patient characteristics, and outcome among these 3 groups

Materials and methods: Patients with mP-NET from 2004 to 2016 were categorized into the 3 groups. Prognosis was calculated using the Kaplan-Meier method. All treatments were recorded and consistency with ENETS guidelines was explored

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Foulfoin M

Authors: Foulfoin F, Graillot E, Adham M, Rousset P, Forestier J,

Keywords: pancreas, metastasis,

To read the full abstract, please log into your ENETS Member account.